Full Press Release Details
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results
and Highlights Recent Business Achievements
Business development: Secures royalty economic interests in two early stage partnered assets
through XOMA Royalty's announced expected acquisition of LAVA Therapeutics.
Company acquisitions: Completed XOMA Royalty's acquisitions of Turnstone Biologics and
HilleVax; announced acquisitions of LAVA Therapeutics and Mural Oncology; acted as
structuring agent for XenoTherapeutics' acquisition of ESSA Pharma.
Key Pipeline advancements: Zevra Therapeutics submitted a Marketing Authorization Application (MAA) with the
European Medicines Agency (EMA) seeking marketing approval for arimoclomol as a treatment for Niemann-Pick Type C; Rezolute Bio reconfirmed its expectations to announce topline data in December from its Phase 3 ersodetug trial in patients
with congenital hyperinsulinism (HI) and announced alignment with FDA on streamlined design for ongoing Phase 3 trial of ersodetug in tumor HI; Gossamer Bio expects topline results from PROSERA, its Phase 3 trial of seralutunib in pulmonary
atrial hypertension (PAH), in February 2026.
Cash receipts: In the first nine months of 2025, XOMA Royalty
received $43.9 million in royalties
and milestones from its partners, including $14.3 million from royalties during the
EMERYVILLE, Calif. - November 12, 2025 (GLOBE NEWSWIRE) - XOMA Royalty Corporation (NASDAQ:
XOMA), the biotech royalty aggregator, reported its 2025 third quarter and year to date financial results and highlighted recent actions that have the potential to deliver additional shareholder value.
"We continue to execute on innovative ways to increase optionality within our portfolio while maintaining a healthy cash balance and limiting dilution
to our shareholders," stated Owen Hughes, Chief Executive Officer of XOMA Royalty. "Growing royalty receipts reflect solid commercial execution on the part of our partners. We look forward to several clinical readouts over the coming
months and quarters that, if positive, can meaningfully shape our business trajectory."
Royalty and Milestone Acquisitions
| Company | Asset and Transaction Detail | |
| LAVA Therapeutics | XOMA Royalty will secure an economic interest in PF-08046052, which is being developed by Pfizer, and JNJ-89853413, which is being developed by Johnson & Johnson, upon closing its acquisition of LAVA. |
Company Acquisitions
| Company | Transaction Details | |
| Turnstone Biologics | XOMA Royalty acquired Turnstone for $0.34 in cash per share of Turnstone common stock plus one non-transferable contingent value right (CVR). | |
| HilleVax | XOMA Royalty acquired HilleVax for a cash payment of $1.95 per share plus a non-transferable CVR that entitles holders to receive certain potential payments. | |
| LAVA Therapeutics | XOMA Royalty will acquire LAVA for (i) an initial cash amount per share of $1.04 plus (ii) a non-transferable CVR per share representing the right to receive certain cash payments, including (A) the previously announced rights to receive, among other things, 75% of the net proceeds related to LAVA's two partnered assets plus 75% of any net proceeds from any out license or sale of LAVA's unpartnered programs, plus (B) a new right to receive up to approximately $0.23 per CVR depending on the final determination after closing of certain potential liabilities. | |
| Mural Oncology | XOMA Royalty will acquire Mural Oncology through its wholly owned subsidiary XRA 5 Corp. for between $2.035 and $2.24 in cash per share. The acquisition is expected to close in the fourth quarter of 2025. 1 , 2 | |
| XenoTherapeutics Acquisition of ESSA Pharma | XOMA Royalty acted as structuring agent for XenoTherapeutics' completed acquisition of ESSA Pharma. |
Pipeline Partner Updates through November 10, 2025
| Partner | Event | |
| Rezolute | In September, Rezolute announced it had achieved alignment with FDA on a significantly streamlined clinical development path for its ongoing Phase 3 study (upLIFT) of ersodetug for the treatment of tumor HI. Topline results are expected in the second half of 2026. 3 | |
| Takeda | The first patient was dosed in Takeda's Phase 3 clinical trial investigating mezagitamab as a treatment for adults with IgA Nephropathy. |
| Zevra Therapeutics | On July 28, Zevra announced it had submitted an MAA to EMA for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC) 4 . | |
| Gossamer Bio | Activated first clinical site for the global, registrational Phase 3 SERANATA study examining seralutinib in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the fourth quarter of 2025 5 . | |
| Dar Biosciences | Announced positive interim safety and efficacy results from its ongoing Phase 3 clinical trial evaluating the contraceptive effectiveness, safety, and acceptability of Ovaprene , an investigational monthly, hormone-free intravaginal contraceptive. 6 |
Anticipated Partner Events of Note through Mid-2026
| Partner | Event | |
| Rezolute | Announces topline data in December 2025 7 from sunRIZE Phase 3 clinical trial, which is investigating ersodetug in infants and children with congenital HI. | |
| Gossamer Bio | Publishes topline results from the Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients 5 . | |
| Dar Bioscience | Makes DARE to PLAY Sildenafil Cream available commercially via prescription in the fourth quarter of 2025 as a compounded drug under Section 503B of the Federal Food, Drug, and Cosmetic Act. 8 Commences one of two registrational Phase 3 clinical trials investigating Sildenafil Cream, 3.6%, for the treatment of female sexual arousal disorder 9 . Discussions with FDA regarding endpoint assessment for Phase 3 clinical studies of Sildenafil Cream, 3.6% continue 8 . | |
| Day One Biopharmaceuticals | Per the Day One conference call held on November 4, 2025, Ipsen, Day One's partner outside the U.S., expects to receive EMA regulatory decision on its application to commercialize tovorafenib in the European Union. |
Third Quarter and Year to Date 2025 Financial Results
Tom Burns, Chief Financial Officer of XOMA Royalty, commented, "In the first nine months of 2025, we have received $43.9 million in cash from
partners, of which $30.3 million were royalty payments related to commercial sales and $13.6 million in milestone payments and fees. In the third quarter, we received $14.3 million in cash from our partners' commercial sales.
With well-executed commercialization efforts by our partners and the emergence of new commercial opportunities from within our portfolio, XOMA Royalty has the potential to become a self-sustaining entity from royalties alone over the near
Income and Revenue: Income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and
$38.4 million, respectively, as compared with $7.2 million and $19.8 million for the corresponding periods of 2024. The increase in both periods presented was primarily driven by increased income related to VABYSMO and OJEMDA.
Research and Development (R&D) Expenses: R&D expenses for the three and nine months ended September 30, 2025, were $69 thousand and
$1.4 million, respectively, compared with $0.8 million and $2.0 million for each of the corresponding periods of 2024. R&D expenses in the first quarter of 2025 and the three- and nine-month periods of 2024 were related to the
clinical trial costs incurred subsequent to XOMA Royalty's acquisition of Kinnate in April 2024 related to KIN-3248 and the associated wind-down activities.
General and Administrative (G&A) Expenses: G&A expenses for the three and nine months ended September 30, 2025, were $9.7 million and
$25.7 million, respectively, as compared with $8.0 million and $27.5 million for the corresponding periods of 2024. The increase of $1.7 million for the three months ended September 30, 2025, as compared to the same period
in 2024, was primarily due to an increase in business development and deal-related costs, partially offset by a decrease in stock-based compensation expense. For the nine months ended September 30, 2025, the decrease of $1.8 million, as
compared to the same period in 2024, was primarily due to costs related to exit packages for Kinnate senior leadership in the second quarter of 2024 and a decrease in stock-based compensation expense, partially offset by an increase in business
development and deal-related costs.
XOMA Royalty's G&A expenses included non-cash stock-based
compensation expenses during the three and nine months ended September 30, 2025, of $1.8 million and $5.4 million, respectively, as compared to $2.6 million and $8.1 million for the corresponding periods of 2024. The 2024
periods reflect non-cash stock-based compensation related to the appointment of Mr. Hughes to full-time Chief Executive Officer and issuance of performance stock units.
Credit Losses on Purchased Receivables: During the nine months ended September 30, 2024, XOMA Royalty recorded
one-time, non-cash credit losses on purchased receivables associated with the Aronora and Agenus assets. To date, there have been no credit losses in 2025.
Amortization of Intangible Assets: Amortization of intangible assets relates to the IP acquired in the Company's acquisitions of Pulmokine in
November 2024 and the mezagitamab economics from the BioInvent transaction in May 2025. Amortization of non-cash intangible assets were $0.9 million and $2.1 million for the three and nine months
ended September 30, 2025.
Gains on Acquisitions: In the third quarter of 2025, XOMA Royalty recorded gains on acquisitions of
$17.9 million for HilleVax and $1.8 million for Turnstone.
Interest Expense: For the three and nine months ended September 30,
2025, interest expense was $3.3 million and $10.0 million, respectively, as compared with $3.5 million and $10.4 million for the corresponding periods of 2024. Interest expense relates to the Blue Owl Loan established in December
Other Income, net: For the three and nine months ended September 30, 2025, other income, net was $0.7 million and
$8.5 million, respectively, as compared with $1.9 million and $5.9 million for the corresponding periods of 2024.
Royalty reported net income of $14.1 million and $25.6 million for the three and nine months ended September 30, 2025, as compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024.
Cash Position: On September 30, 2025, XOMA Royalty had cash and cash equivalents of $130.6 million, including $85.4 million in
restricted cash. The restricted cash balance included $43.3 million related to the assumed HilleVax lease, $39.9 million reserved to fund the Mural acquisition, and $2.2 million related to the Blue Owl Loan. Cash and cash equivalents
of $106.4 million as of December 31, 2024, included $4.8 million in restricted cash related to the Blue Owl Loan.
In the third quarter of
2025, XOMA Royalty received $14.3 million in cash receipts from royalties and commercial payments and paid $1.4 million in dividends on the XOMA Royalty Perpetual Preferred stocks. In the first nine months of 2025, XOMA Royalty received
$43.9 million in cash receipts, including $30.3 million in royalties and commercial payments and $13.6 million in milestone payments and fees. During the first nine months of 2025, XOMA Royalty deployed $25.0 million to acquire
additional assets for its royalty and milestone portfolio, repurchased approximately 108,510 shares of its common stock for a cost of $2.4 million, and paid $4.1 million in dividends on the XOMA Royalty Perpetual Preferred stocks.
About XOMA Royalty Corporation
biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with
pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing
portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com
or follow XOMA Royalty Corporation on LinkedIn.
Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA Royalty and other developments related to
VABYSMO (faricimab-svoa), OJEMDA (tovorafenib), MIPLYFFA (arimoclomol),
XACIATO (clindamycin phosphate) vaginal gel 2%, IXINITY [coagulation factor IX (recombinant)], DSUVIA (sufentanil sublingual tablet), and Sildenafil Cream, 3.6%; the potential occurrences of the events listed under "Anticipated 2025 Events of Note"; the anticipated timings of
regulatory filings and approvals related to assets in XOMA Royalty's portfolio; and the potential of XOMA Royalty's portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over
time. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek,"
"project," "expect," "may," "will", "would," "could" or "should," the negative of these terms or similar expressions. These forward-looking statements are not a
guarantee of XOMA Royalty's performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those
anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our
licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the
therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in
more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's
prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent
date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.
EXPLANATORY NOTE: Any
references to "portfolio" in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to "assets" in this press release refer strictly
to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets
in XOMA Royalty's milestone and royalty portfolio are VABYSMO (faricimab-svoa), OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate) vaginal gel 2%, IXINITY
[coagulation factor IX (recombinant)], and DSUVIA (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety
have not been established. There is no guarantee that any of the investigational compounds will become commercially available.
XOMA ROYALTY CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
thousands, except share and per share amounts)
| Three Months Ended | Nine Month Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Income and Revenues: | ||||||||||||||||
| Income from purchased receivables under the EIR method | $ | 6,962 | $ | 5,423 | $ | 19,039 | $ | 9,985 | ||||||||
| Income from purchased receivables under the cost recovery method | 1,857 | 1,040 | 9,125 | 1,910 | ||||||||||||
| Revenue from contracts with customers | 225 | 25 | 9,250 | 6,050 | ||||||||||||
| Revenue recognized under units-of-revenue method | 307 | 709 | 978 | 1,828 | ||||||||||||
| Total income and revenues | 9,351 | 7,197 | 38,392 | 19,773 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 69 | 817 | 1,431 | 2,011 | ||||||||||||
| General and administrative | 9,734 | 8,020 | 25,682 | 27,485 | ||||||||||||
| Credit losses on purchased receivables | - | 14,000 | - | 23,000 | ||||||||||||
| Amortization of intangible assets | 878 | - | 2,077 | - | ||||||||||||
| Total operating expenses | 10,681 | 22,837 | 29,190 | 52,496 | ||||||||||||
| Income (Loss) from operations | (1,330 | ) | (15,640 | ) | 9,202 | (32,723 | ) | |||||||||
| Other income (expense) | ||||||||||||||||
| Gains on acquisitions | 18,004 | - | 18,004 | 19,316 | ||||||||||||
| Change in fair value of embedded derivative related to RPA | - | - | - | 8,100 | ||||||||||||
| Interest expense | (3,301 | ) | (3,493 | ) | (10,004 | ) | (10,446 | ) | ||||||||
| Other income, net | 727 | 1,890 | 8,456 | 5,900 | ||||||||||||
| Net income | $ | 14,100 | $ | (17,243 | ) | $ | 25,658 | $ | (9,853 | ) | ||||||
| Income tax expense | $ | (49 | ) | $ | - | $ | (49 | ) | $ | - | ||||||
| Net income (loss) | $ | 14,051 | $ | (17,243 | ) | $ | 25,609 | $ | (9,853 | ) | ||||||
| Net income (loss) available to (attributable to) common stockholders, basic | $ | 8,981 | $ | (18,611 | ) | $ | 15,192 | $ | (13,957 | ) | ||||||
| Basic net income per share available to common stockholders | $ | 0.74 | $ | (1.59 | ) | $ | 1.26 | $ | (1.20 | ) | ||||||
| Weighted average shares used in computing basic net income per share available to common stockholders | 12,137 | 11,712 | 12,038 | 11,645 | ||||||||||||
| Net income (loss) available to (attributable to) common stockholders, diluted | $ | 12,683 | $ | (18,611 | ) | $ | 21,505 | $ | (13,957 | ) | ||||||
| Diluted net income per share available to common stockholders | $ | 0.70 | $ | (1.59 | ) | $ | 1.20 | $ | (1.20 | ) | ||||||
| Weighted average shares used in computing diluted net income per share available to common stockholders | 18,141 | 11,712 | 17,932 | 11,645 |
XOMA ROYALTY CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
thousands, except share and per share amounts)
| September 30, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 45,189 | $ | 101,654 | ||||
| Short-term restricted cash | 45,288 | 1,330 | ||||||
| Investment in equity securities | 1,521 | 3,529 | ||||||
| Trade and other receivables, net | 3,573 | 1,839 | ||||||
| Short-term royalty and commercial payment receivables under the EIR method | 13,269 | 14,763 | ||||||
| Short-term royalty and commercial payment receivables under the cost recovery method | 900 | 413 | ||||||
| Prepaid expenses and other current assets | 967 | 2,076 | ||||||
| Total current assets | 110,707 | 125,604 | ||||||
| Long-term restricted cash | 40,076 | 3,432 | ||||||
| Property and equipment, net | 24 | 32 | ||||||
| Operating lease right-of-use assets | 272 | 319 | ||||||
| Long-term royalty and commercial payment receivables under the EIR method | 4,678 | 4,970 | ||||||
| Long-term royalty and commercial payment receivables under the cost recovery method | 57,864 | 55,936 | ||||||
| Exarafenib milestone asset | 3,500 | 3,214 | ||||||
| Investment in warrants | 595 | - | ||||||
| Intangible assets, net | 44,556 | 25,909 | ||||||
| Other assets - long term | 879 | 1,861 | ||||||
| Total assets | $ | 263,151 | $ | 221,277 | ||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,654 | $ | 1,053 | ||||
| Accrued and other liabilities | 4,134 | 5,752 | ||||||
| Contingent consideration under RPAs, AAAs, and CPPAs | - | 3,000 | ||||||
| Operating lease liabilities | 2,508 | 446 | ||||||
| Unearned revenue recognized under units-of-revenue method | 1,320 | 1,361 | ||||||
| Preferred stock dividend accrual | 1,368 | 1,368 | ||||||
| Current portion of long-term debt | 14,345 | 11,394 | ||||||
| Contingent value rights liabilities - current portion | 1,976 | - | ||||||
| Total current liabilities | 28,305 | 24,374 | ||||||
| Unearned revenue recognized under units-of-revenue method - long-term | 3,473 | 4,410 | ||||||
| Exarafenib milestone contingent consideration | 3,500 | 3,214 | ||||||
| Long-term operating lease liabilities | 20,678 | 483 | ||||||
| Long-term debt | 94,382 | 106,875 | ||||||
| Contingent value rights liabilities - long-term | 4,807 | - | ||||||
| Deferred tax liability | 49 | - | ||||||
| Total liabilities | 155,194 | 139,356 | ||||||
| Convertible preferred stock, $0.05 par value, 5,003 shares authorized, issued and outstanding as of September 30, 2025 and December 31, 2024 | 20,019 | 20,019 | ||||||
| Stockholders' equity: | ||||||||
| 8.625% Series A cumulative, perpetual preferred stock, $0.05 par value, 984,000 shares authorized, issued and outstanding as of September 30, 2025 and December 31, 2024 | 49 | 49 | ||||||
| 8.375% Series B cumulative, perpetual preferred stock, $0.05 par value, 3,600 shares authorized, 1,600 shares issued and outstanding as of September 30, 2025 and December 31, 2024 | - | - | ||||||
| Common stock, $0.0075 par value, 277,333,332 shares authorized, 12,310,300 and 11,952,377 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 92 | 90 | ||||||
| Additional paid-in capital | 1,301,542 | 1,298,747 | ||||||
| Accumulated other comprehensive income | 121 | 73 | ||||||
| Accumulated deficit | (1,213,866 | ) | (1,237,057 | ) | ||||
| Total stockholders' equity | 87,938 | 61,902 | ||||||
| Total liabilities, convertible preferred stock and stockholders' equity | $ | 263,151 | $ | 221,277 |
XOMA ROYALTY CORPORATION